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Abstract: Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic 
alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart 
surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can al-
ter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the de-
velopment of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA anti-
body production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before 
transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) con-
sequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated 
rejection after transplantation.  
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CAUSES OF ANTI-HLA ANTIBODY PRODUCTION 
  Anti-HLA antibodies usually can be detected in the blood 
of individuals in response to an exposure to foreign antigens 
that stimulate their production. Various stimuli have been 
identified that result in the development of anti-HLA anti-
bodies. These include pregnancy, transfusions of blood 
products, valved and non-valved allograft material (includ-
ing whole organ transplant), and use of ventricular assist de-
vices. Blood transfusions cause anti-HLA antibody produc-
tion through exposure to antigenic stimuli such as white 
blood cells and/or platelets. Using filters and/or irradiation 
reduces the risk of HLA allosensitization, but does not ap-
pear to be entirely protective. Patients who undergo repair of 
CHD, especially if requiring cardiopulmonary bypass, usu-
ally are exposed to blood products either during or after sur-
gery. Many patients with CHD, particularly those with com-
plex CHD, often require multiple surgeries throughout their 
lifetimes, and therefore are exposed to multiple blood prod-
ucts and therefore multiple antigenic stimuli. Valved and 
non-valved allograft material is commonly used for the re-
pair of CHD. Valved allograft material is used for repairs in 
the right and left ventricular outflow tracts, and much less 
commonly in the atrioventricular valves. Non-valved al-
lograft material is used primarily for aortic arch and pulmo-
nary artery reconstruction, in addition to right and left ven-
tricular outflow tracts. Regardless of its site of repair, al-
lograft material used at the time of surgery provides a strong 
stimulus to the development of anti-HLA antibodies. This 
response occurs within weeks of implantation and can be de-
tected as circulating very broad reactivity of anti-HLA anti-
bodies for many years [1-5]. 
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PREVENTIVE STRATEGIES FOR ANTI-HLA ANTI-
BODY PRODUCTION BEFORE TRANSPLANTA-
TION 
  Two basic strategies have been tried to prevent the de-
velopment of anti-HLA antibodies in these situations: 1) the 
reduction and/or alteration of the antigenic stimulus, or 2) 
the alteration of the immune response of the individual to the 
antigenic stimulus. As stated above, using filters and/or irra-
diation for blood products may decrease the antigenic expo-
sure to an individual, and the mechanism is thought to be 
primarily through the removal of allosensitizing white blood 
cells in blood products. Attempts to alter the antigenic load 
that is presented by allograft material has generally been di-
rected toward removal of antigen-presenting cells on al-
lograft material prior to implantation. These decellularized 
allografts have been shown to markedly reduce the degree of 
allosensitization seen after allograft implantation in both 
animals and in humans, but questions still remain as to the 
durability and safety of these altered allografts [6-9].  
  Methods to alter the immune system before or during al-
lograft implantation has also met with some degree of suc-
cess. In animal studies, drugs like cyclosporine and myco-
phenolic mofetil (MMF) have been successfully used to re-
duce the alloantibody response to allograft implantation [10, 
11]. Peri-operative MMF (but not azathioprine) has also 
been shown to reduce the response to allograft implantation 
in children undergoing surgery for CHD [12-14]. Presuma-
bly, if patients with CHD were heavily immunosuppressed at 
the time of allograft implantation for repair of CHD (similar 
to heart transplantation), there would be significant reduction 
in the incidence and breadth of allosensitization. However, 
this level of immunosuppression carries with it significant 
risks including infectious and neoplastic complications, in 
addition to all of the drug-specific complications such as re-
nal dysfunction, diabetes, etc. One of the factors limiting the 
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allograft implantation for CHD is the lack of convincing evi-
dence that the anti-HLA antibody response to the allograft 
alters its function and/or longevity. Thus, it is difficult to jus-
tify routine immunosuppression in children with CHD who 
receive allograft material at the time of surgery. 
  The consequences of the development of anti-HLA anti-
bodies in patients with CHD are a matter of debate [15]. Al-
though one would theorize that the presence of donor-
specific anti-HLA antibodies has potential for immune-
mediated damage to the implanted allograft, it has never 
been conclusively proven that this is true. Some pathologic 
studies of explanted allografts in adults have failed to dem-
onstrate evidence of immune-mediated damage (e.g., “rejec-
tion”) [16]. However, evidence of such immune injury in ex-
planted allografts of children with CHD has been shown [17 
18]. There do not appear to be any other significant systemic 
adverse effects from these alloantibodies, unless these pa-
tients come to need heart or other solid organ transplantation. 
It has been well-recognized for many years that patients with 
circulating anti-HLA antibodies, especially those who have a 
subsequent incompatible HLA crossmatch because of these 
antibodies, are at increased risk for rejection and graft loss 
after transplantation for [19, 20]. Because of this, many cen-
ters continue to maintain a policy of requiring a prospective 
crossmatch (either actual crossmatch between donor and re-
cipient, or virtual crossmatch based upon known HLA donor 
type and recipient anti-HLA antibodies. In these situations 
where a prospective crossmatch is required (either actual or 
virtual), wait times for organs are significantly increased due 
to the resultant reduction in potential donors, and therefore 
waitlist mortality is significantly increased. In pediatrics, 
wait times to transplant and mortality after listing have been 
shown to be double those who do not require a crossmatch 
[21]. Because of this, some centers have adopted a policy of 
not requiring a prospective crossmatch, and performing heart 
transplants with an incompatible HLA match. Using plas-
mapheresis, thymoglobulin, and increased immunosuppres-
sion, early results have been encouraging, and multicenter 
studies are underway [22-24]. 
TREATMENT STRATEGIES FOR THOSE PATIENTS 
WHO DEVELOP ANTI-HLA ANTIBODIES BEFORE 
TRANSPLANTATION  
  Many strategies have been tried to reduce this allosensiti-
zation before transplantation in order to optimize the oppor-
tunity for finding and transplanting an HLA-compatible or-
gan. These strategies have included plasmapheresis, a proce-
dure which involves extracorporeal removal and replacement 
of the entire plasma volume (containing antibodies as well as 
other proteins such as coagulation factors). Plasmapheresis 
requires placement of a large bore dual lumen catheter in a 
large central vein. This is often challenging in young chil-
dren due to size of blood vessels, lack or minimal vascular 
access because of venous occlusions from previous catheters, 
and/or systemic venous anomalies. Exchange transfusions 
are often performed in children who are too small for vascu-
lar catheter placement and plasmapheresis. Additional strate-
gies include immunosuppressant medications (such as cyclo-
phosphamide), intravenous immune globulin (IVIG), rituxi-
mab, or some combination of these [25-27]. Most of   
 
these strategies have been able to demonstrate at least a 
modest, although transient, reduction in anti-HLA antibodies 
in some patients. Unfortunately, none of these strategies ap-
pear to result in a sustained reduction; furthermore, there is 
controversy as to whether this transient reduction in anti-
HLA antibodies provides enough improvement in outcomes 
after transplantation to warrant the exposure to the medica-
tions, hospitalizations, and risks of these treatments.  
CONSEQUENCES OF HLA ALLOSENSITIZATION 
AFTER TRANSPLANTATION  
  The presence of circulating anti-HLA antibodies before 
transplantation is associated with increased risk of rejection, 
graft vasculopathy, graft dysfunction, and death after trans-
plantation [28-31]. Injury to the graft may be acute with 
hemodynamic dysfunction or more chronic manifesting as 
chronic rejection or graft vasculopathy. Donor specific anti –
HLA antibodies (DSA) may be preformed due to allosensiti-
zation prior to transplant, or develop de novo at any time fol-
lowing transplant. The de novo development of anti-HLA 
antibodies after heart transplantation correlates with de-
creased long term survival. Patients with de novo antibodies 
appearing more than one year following transplantation had 
the poorest survival; 47% at 15 years compared to 70-71% 
15 year survival for those with none or only pre transplant 
anti-HLA antibodies [32]. 
  Most investigations refer to results of generalized anti-
HLA panel reactive antibody (PRA) assays rather than donor 
specific antibodies for determination of allosensitization 
status. Data from the United Network for Organ Sharing 
/Organ Procurement and Transplantation Network (UNOS/ 
OPTN) shows that elevated pretransplant PRA in adult heart 
transplant recipients is a strong predictor of rejection within 
1 year after transplant and mortality [33]. The potential con-
sequence of DSAs on transplant outcomes in children is less 
well established, and may not be the same as observed in 
adults due to putative age-related differences in the maturity 
of the immune system. The incidence of allosensitized pedi-
atric heart transplant candidates appears to be increasing as 
our CHD population enjoys improved operative survival, 
only to eventually develop cardiac dysfunction following 
palliative repair. Coupled with a persistently limited pediat-
ric donor supply, the impact of DSA on pediatric heart trans-
plant outcomes is a current area of significant research ef-
forts.  
  Data available for pediatric heart transplant recipients is 
generally limited by small sample sizes from single center 
reports with heterogeneous results due to variations in study 
design or antibody detection methods. There is a consensus 
that DSA can be detrimental to graft function, and associated 
with rejection, though findings related to impact of DSA on 
graft and patient survival is less uniform [21,24, 34-36].  
  In a recent study from the UNOS registry, pediatric heart 
transplant recipients with PRA >10% had significantly worse 
graft and patient survival than those with none or PRA of 
1%-10% [37]. Findings were independent of pretransplant 
status, year of transplantation, donor factors, crossmatch 
status, and rejection episodes in the first year after transplant. 
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  There is increasing evidence that anti-HLA antibodies 
(elevated PRA) are involved in cardiac allograft injury, both 
acute and chronic, referred to as humoral or antibody-
mediated rejection (AMR). Diagnostic criteria for AMR are 
controversial; however they currently include clinical evi-
dence of cardiac graft dysfunction, donor- specific anti HLA 
antibodies in the serum, and pathologic findings on endo-
myocardial biopsy. These pathologic findings may include 
one or both of the following: histologic abnormalities (capil-
lary injury with endothelial cell swelling, intravascular 
macrophage and/or neutrophil accumulation) as well as im-
munostaining abnormalities (immunofluorescent deposits of 
immunoglobulin and complement diffusely in the vascula-
ture) [38, 39].  
  The most severe form of AMR is referred to as hy-
peracute rejection which occurs in the first hours after trans-
plant, precipitated by the presence of pre-formed DSA in the 
circulation that activates the complement system resulting in 
severe lytic injury to the endothelium and the graft, resulting 
in severe dysfunction (similar mechanism as injury due to 
ABO incompatibility). Chronic complement activation with 
sublytic injuries may occur in transplant recipients with DSA 
and/or elevated PRA as an ongoing or intermittent process 
that results in AMR and graft dysfunction. Acute hemody-
namic compromise with increased risk for death, and devel-
opment of early transplant graft vasculopathy has been ob-
served in both adults and children with AMR that occurs af-
ter the immediate postoperative period [31]. The develop-
ment of AMR has a significant negative impact on 15 year 
graft survival, with only 16% survival in AMR(+) patients 
compared to 63% survival in those without AMR in one 
study [40]. Of the 23 patients with AMR in this study, 21 
displayed cytotoxic DSA at the time of diagnosis. While the 
presence of DSA and elevated PRA have been associated 
with detrimental outcomes, the mechanism has not been di-
rectly studied in most clinical investigations. There is some 
debate as to the uniform ability of all anti HLA antibodies to 
activate the complement system and cause graft injury. The 
potential for accommodation has also been considered. 
TREATMENT OF HLA ALLOSENSITIZATION AND 
ANTIBODY-MEDIATED REJECTION AFTER 
TRANSPLANTATION  
  Treatment of antibody – mediated rejection following 
heart transplant is focused on elimination of circulating anti-
bodies, inhibition of circulating antibodies, suppression of B 
cells, plasma cell depletion, and/or complement inhibition, in 
addition to support of graft function which is often impaired 
due to immune-mediated injury [41]. Attempts to remove 
antibody are most commonly performed with plasmaphere-
sis. Sedation may be required for catheter placement, which 
has risks if the patient is experiencing hemodynamic com-
promise from AMR. Fluid shifts, calcium and other electro-
lyte flux, and systemic reactions to blood products used for 
plasma replacement, are other risks related to plasmapheresis 
and/or exchange transfusion. Immune apheresis (immunoad-
sorption) is an emerging modality to specifically remove cir-
culating antibodies and immune complexes. Plasmapheresis 
is often accompanied by the use of high-dose IVIG for im-
munomodulation to block anti-HLA antibody activity and 
inhibit complement, as well as corticosteroids to further at-
tenuate the negative effect of circulating antibodies. Thera-
pies to specifically target B cells are often incorporated into 
treatment for AMR. Rituximab is a chimeric murine/human 
anti CD20 monoclonal antibody that is utilized to deplete B 
cells and interfere with antigen-presenting cell (APC) activ-
ity to attempt to reduce the risk of recurrent AMR. While 
most reports have shown utility in treating AMR, all are 
small case series with different response rates and treatment 
protocols, combining various doses of rituxumab with IVIG, 
steroid and plasmapheresis. Serious infections are a notable 
side effect observed with rituximab therapy [42]. New thera-
pies are constantly being sought since the current methods 
are not universally successful. Bortezomib is an example of a 
proteosome l inhibitor that has anti plasma cell properties 
and therefore is a promising therapy for AMR. Effectiveness 
of bortezomib against AMR in kidney transplant recipients 










Fig. (1). Kaplan–Meier survival curve with log–rank statistics for graft and patient survival. PRA, Panel-reactive antibody. (With permission, 
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specific anti-human leukocyte antigen antibody [43]. This 
therapy remains in early stages of investigation. 
  Support of the patient with significant cardiac graft dys-
function due to AMR may require intravenous inotropes, 
(milrinone, dobutamine, dopamine) and even temporary me-
chanical circulatory support due to acute hemodynamic de-
compensation. Following an episode of AMR, a change and/ 
or increase in doses of maintenance immunosuppression is 
often considered. This may entail replacement of cyclos-
porine with tacrolimus in patients receiving cyclosporine-
based immunosuppression, change in antiproliferative agents 
from azathioprine to MMF, addition of rapamycin (mammal-
ian target of rapamycin inhibitor), and/ or corticosteroids.  
  Cardiac catheterization for assessment of hemodynamics 
and endomyocardial biopsies including immunohistochemis-
try examination should be considered within weeks after ini-
tiation of AMR therapy to help assess effectiveness of ther-
apy. Graft dysfunction may be prolonged.  
  Emergent listing for retransplantation can be considered 
if the above measures do not restore acceptable cardiac func-
tion. However, retransplantation in first 6 months following 
heart transplant and or for acute rejection is not recom-
mended by the International Society of Heart and Lung 
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